A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

  • End date
    Dec 30, 2023
  • participants needed
  • sponsor
    BioInvent International AB
Updated on 10 March 2022


Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab


This is a Phase 1/2a, dose escalation, consecutive-cohort, open-label studytrial of BI-1206 in combination with rituximab in subjects with indolent relapsed or refractory B-cell NHL. The studytrial will consist of 2 main parts: Phase 1 (with dose escalation cohorts using a 3+3 dose-escalation design and selection of the RP2D), and Phase 2a (the escalationexpansion cohort at the RP2D). Subjects in each phase will receive 1 cycle (4 doses) of induction therapy with BI-1206 in combination with rituximab. Subjects who show clinical benefit (complete response [CR], partial response [PR], or stable disease [SD]) at Week 6 will continue onto maintenance therapy and receive BI-1206 and rituximab once every 8 weeks (relative to previous maintenance dose) for up to 6 maintenance cycles, or up to 1 year from first dose of BI-1206 (whichever occurs first).

Condition Indolent B-Cell Non-Hodgkin Lymphoma
Treatment BI1206
Clinical Study IdentifierNCT03571568
SponsorBioInvent International AB
Last Modified on10 March 2022


Yes No Not Sure

Inclusion Criteria

Are ≥ 18 years of age by initiation of study treatment
Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL3B), MCL and marginal zone lymphoma (MZL)
Have measureable nodal disease
Are willing to undergo lymph node biopsies or biopsies of other involved tissue
Have relapsed disease or disease refractory to conventional treatment or for which no standard therapy exists
Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen
Have a life expectancy of at least 12 weeks
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Have CD20+ malignancy
Have hematological and biochemical indices within prespecified ranges

Exclusion Criteria

Have had an allogenic bone marrow or stem cell transplant within 12 months
Have presence of active chronic graft versus host disease
Have current leptomeningeal lymphoma or compromise of the central nervous system
Have transformed lymphoma from a pre-existing indolent lymphoma
Have Waldenstrom's Macroglobulinemia or FL3B
Need systemic doses of prednisolone >10 mg daily (or equipotent doses of other corticosteroids) while on the study trial other than as pre-medication
Have known or suspected hypersensitivity to rituximab or BI-1206
Have cardiac or renal amyloid light-chain amyloidosis
Have received the following
Chemotherapy or small molecule products with 2 weeks of first dose of BI-1206
Radiotherapy (except for focal symptomatic control of lymphadenopathy) within 4 weeks
Immunotherapy within 8 weeks
Have ongoing toxic manifestations of previous treatments
Have the ability to become pregnant (or already pregnant or lactating/breastfeeding)
Have had major surgery from which the subject has not yet recovered
Are at high medical risk because of non-malignant systemic disease including active infection on treatment with antibiotics, antifungals or antivirals
Are serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Have an active, known or suspected autoimmune disease
Have concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA])
Have current malignancies of other types
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note